BioLine Rx (XTAE:BLRX) 5-Year EBITDA Growth Rate : 29.40% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx 5-Year EBITDA Growth Rate?

BioLine Rx's EBITDA per Share for the three months ended in Dec. 2023 was ₪-0.05.

During the past 3 years, the average EBITDA Per Share Growth Rate was 18.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 29.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 25.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioLine Rx was 42.80% per year. The lowest was 12.70% per year. And the median was 25.00% per year.

Competitive Comparison of BioLine Rx's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, BioLine Rx's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where BioLine Rx's 5-Year EBITDA Growth Rate falls into.

BioLine Rx 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

BioLine Rx (XTAE:BLRX) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

BioLine Rx 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of BioLine Rx's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.